Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.6% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment reporting

Analytics

Phase 2

8(88.9%)

Phase 1/2

1(11.1%)

9Total

Phase 2(8)

Phase 1/2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04968106Phase 2Active Not Recruiting

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

Role: lead

NCT05346848Phase 2Recruiting

Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer

Role: lead

NCT03915678Phase 2Active Not Recruiting

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Role: lead

NCT04874311Phase 2Active Not Recruiting

Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma

Role: lead

NCT04807816Phase 2Completed

Targeting ATR in Soft-tissue Sarcomas

Role: lead

NCT04095208Phase 2Completed

Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study

Role: lead

NCT04880382Phase 2Terminated

Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer Patients

Role: lead

NCT06084689Phase 2Withdrawn

Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

Role: lead

NCT03475953Phase 1/2Unknown

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Role: lead

All 9 trials loaded